LETYBO

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Cyprus, Estonia, France, Ireland, Italy, Lithuania, Malta, Romania, Spain, UK.

Active ingredients

The drug LETYBO contains one active pharmaceutical ingredient (API):

1	Botulinum toxin type A UNII E211KPY694 - BOTULINUM TOXIN TYPE A
	Botulinum toxin type A is a protein complex derived from Clostridium botulinum. The protein consists of type A neurotoxin and several other proteins. Under physiological conditions it is presumed that the complex dissociates and releases the pure neurotoxin. Intramuscular injection of the neurotoxin complex blocks cholinergic transport at the neuromuscular junction by preventing the release of acetylcholine. The nerve endings of the neuromuscular junction no longer respond to nerve impulses and secretion of the chemotransmitter is prevented (chemical denervation).
	Read more about Botulinum toxin type A

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LETYBO Powder for solution	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M03AX01	Botulinum toxin	M Musculo-skeletal system → M03 Muscle relaxants → M03A Muscle relaxants, peripherally acting agents → M03AX Other muscle relaxants, peripherally acting agents
Discover more medicines within M03AX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02528134, 02528142
EE	Ravimiamet	3034875, 3034886, 3034909
ES	Centro de información online de medicamentos de la AEMPS	87951
FR	Base de données publique des médicaments	69878363
HR	Agencija za lijekove i medicinske proizvode	HR-H-413273619
IT	Agenzia del Farmaco	048945012, 048945024, 048945036, 048945048
LT	Valstybinė vaistų kontrolės tarnyba	1098473, 1098474, 1098475, 1098476
MT	Medicines Authority	MA1493/00101
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68682001, W68682002, W68682003
US	FDA, National Drug Code	81165-050, 81165-100